2024-11-04 - Analysis Report
## Vertex Pharmaceuticals Inc (VRTX) Stock Analysis Report 

**1. Performance vs. S&P 500 (VOO)**

Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company focused on developing and commercializing therapies for serious diseases. 

VRTX has outperformed the S&P 500 (VOO) by a significant margin, with a cumulative return of 172.73% compared to VOO's 131.78%. This represents a difference of **40.95%**, which places it in the 74.98% percentile of historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|-----|-------|------|
| 2015 | 4.4% | 29.8% | 4.0% | 0.0 |
| 2016 | -41.8% | 35.1% | -51.3% | -4.4 |
| 2017 | 57.3% | 13.8% | 37.9% | 3.0 |
| 2018 | 9.2% | 19.3% | 19.8% | -0.9 |
| 2019 | 35.7% | 13.2% | 4.7% | 1.1 |
| 2020 | 6.8% | 30.3% | -13.5% | 0.3 |
| 2021 | -23.4% | 23.4% | -62.6% | -0.6 |
| 2022 | 36.0% | 17.2% | 81.6% | -0.8 |
| 2023 | 61.0% | 10.3% | 26.5% | 1.8 |
| 2024 | 27.4% | 10.8% | -6.1% | 0.8 |

**Analysis:** VRTX exhibits a relatively high beta, indicating it's more volatile than the market. However, its positive alpha values throughout most of the analyzed period suggest it has outperformed the market by a considerable margin.

**2. Recent Price Movements:**

* Closing Price: **471.12**
* 5-day Moving Average: **473.78**
* 20-day Moving Average: **475.65**
* 60-day Moving Average: **474.58**

VRTX is trading slightly below its short-term moving averages, potentially indicating a slight downward trend. 

**3. Technical Indicators:**

* **RSI:** 40.09 - This suggests VRTX is currently in a neutral zone, not oversold or overbought.
* **PPO:** -0.14 - A negative PPO indicates a potential downward trend.
* **Delta_Previous_Relative_Divergence:** 5.85 (+) - This indicates a short-term upward trend.
* **Expected Return:** 5.88% - This is the projected long-term (2+ years) outperformance potential compared to the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

**Analysis:** The most recent earnings report (2024-08-02) showed a significant decline in EPS, which was below analyst estimates. This may have contributed to the recent price decline. Further analysis is needed to understand the underlying factors contributing to the EPS decline.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |
| 2023-09-30 | $2.48B | 87.17% |
| 2023-06-30 | $2.49B | 87.62% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93% |
| 2023-12-31 | $17.58B | 5.51% |
| 2023-09-30 | $16.51B | 6.27% |
| 2023-06-30 | $15.47B | 5.92% |

**Analysis:** VRTX maintains a strong profit margin and healthy revenue growth. However, the recent decline in ROE may be a cause for concern, especially considering the negative EPS in the latest quarter.

**6. News and Recent Issues:**

* **Recent Earnings News:** The August 2024 earnings release reported a decline in EPS, which was below analyst expectations. This news likely contributed to the recent price dip. You can refer to Shacknews and similar financial news sources for detailed analysis of the earnings report.
* **Recent Market Outlook:** While VRTX has historically outperformed the market, the recent earnings miss and market volatility have created a more uncertain outlook for the company. It is crucial to monitor analyst opinions and market trends closely.
* **Analyst Opinions and Performance Highlights:** Refer to Finbold and similar financial websites for the latest analyst opinions and performance highlights for VRTX.

**7. Overall Analysis:**

VRTX has historically been a strong performer, with high growth and a track record of outperforming the market. However, the recent earnings miss raises some concerns. The stock is currently trading below its short-term moving averages, indicating potential downside pressure. The technical indicators are neutral, but the negative PPO suggests caution. Despite the recent challenges, VRTX's long-term outlook remains positive based on its expected return, strong profitability, and position in the biotechnology market. Investors should closely monitor the company's performance and upcoming news releases to make informed decisions.